RRMM Navigating New Treatment Paradigms
|When First-Line Treatment Fails: Navigating New Treatment Paradigms in Relapsed/Refractory Multiple Myeloma|
CME, CPE, CNE
Andrzej Jakubowiak, MD, PhD and Philip L. McCarthy, MD
|Release Date: November 21, 2016|
Expiration Date: November 21, 2017
The treatment of multiple myeloma (MM) has changed dramatically in the past several years, with numerous innovations resulting in signiﬁcant improvement in outcomes and long-term survival for many patients. Despite the new advances, however, signiﬁcant challenges remain, particularly in patients with relapsed/refractory multiple myeloma (RRMM). To support an increased understanding of new therapeutic choices in the treatment of RRMM and to provide practical education that delivers up-to-date information, expert faculty will share their latest insights and experiences. During this activity, recorded from a live meeting in Chicago in September 2016, we will discuss recent advances in the treatment of relapsed/refractory disease and how to navigate among the current agents to ﬁnd the right treatment option for your patients. This program will describe new agents used in practice today, review current guidelines, share best practices, and review patient-centered treatment strategies in RRMM.Provided by The University of Texas MD Anderson Cancer Center and MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Inc., Bristol-Myers Squibb Company and Takeda Oncology.
|Begin, Earn CreditView Only, No Credit|